Prospective Study of White Blood Cells

NCT ID: NCT04838171

Last Updated: 2026-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-24

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Diseases Inflammation Rejection; Transplant, Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Specimen collection to support development of engineering Treg

White blood cell and blood collection

Intervention Type OTHER

Mononucleocytes will be collected via apheresis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

White blood cell and blood collection

Mononucleocytes will be collected via apheresis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Quell Therapeutics Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Quell Investigator Site 01

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gareth Wright

Role: CONTACT

+4(0)2070969012

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

QEL-RP-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Immune Cell Response to Stimuli
NCT00397280 RECRUITING
Third Party Viral Specific T-cells (VSTs)
NCT02532452 RECRUITING PHASE2
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058 NOT_YET_RECRUITING PHASE1/PHASE2